WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPDI) today announced it has opened its global central lab facility in Singapore, strengthening its ability to provide biopharmaceutical clients an extensive range of customized laboratory services in Southeast Asia, a high-growth region for clinical research.

“Expanding our global central lab services into Singapore demonstrates our commitment to deliver high quality specimens and laboratory results for our clients in a growing biopharmaceutical market,” said Steve Lobel, vice president, global laboratory operations, PPD. “We can expedite delivery of lab data through reduced transportation and shipping time at better logistics costs for our clients.”

PPD also has an office in Singapore where for more than 10 years it has provided a range of clinical development services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.

The laboratory instrumentation and standards in Singapore are identical to platforms located at PPD’s global central labs in Brussels, Belgium; Highland Heights, Ky.; and Beijing, China. Assays are extensively cross validated among all PPD locations to produce combinable data. The Singapore lab interfaces directly with ConneXion, the company’s proprietary single global database, to ensure consistent management and real-time reporting. Clients can view and analyze laboratory results from all lab locations using PPD Clicks™, a secure Web site launched last year.

PPD’s lab is located at 61 Science Park Road #02-12/14, Singapore Science Park II Singapore 117525. For more information about PPD’s global central lab capabilities, contact Dean Hass, vice president, business development, at +1 913 681 5854 or at dean.hass@ppdi.com.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 38 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the impact of PPD’s global central lab in Singapore, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: success in sales growth; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; loss of large contracts; the ability to attract and retain key personnel; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; increased cancellation rates; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.